In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
T KasperskiDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.ORCID 0000-0003-4254-2804 R Arazo Del PinoInstitute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0009-0000-4592-5742 K XanthopoulouInstitute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-8591-8184 T BurgwinkelInstitute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0009-0002-4910-4655 M Pomorska-WesołowskaDepartment of Microbiology, Analytical and Microbiological Laboratory of Ruda Slaska, KORLAB NZOZ, Ruda Slaska, Poland.
J Wójkowska-MachDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.ORCID 0000-0003-0756-1639 A ChmielarczykDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.ORCID 0000-0002-0814-8638 P G HigginsInstitute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0001-8677-9454 Funding
Narodowe Centrum Nauki 2020/39/O/NZ7/00145
6 · The paper itselfAbstract
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsBacterial Proteinsbeta-LactamasesPlasmidsAnti-Bacterial AgentsCarbapenemsDisease OutbreaksHumansMicrobial Sensitivity TestsMultilocus Sequence TypingPolandWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsOXA-72 carbapenemase, Acinetobacter baumanniiAcinetobacter baumanniiblaOXA-1223blaOXA-23blaOXA-72carbapenem resistancecore genome MLST (cgMLST)GR2 plasmidinternational clone 2 (IC2)whole-genome sequencing (WGS)
Identifiers
PMID42360170
PMCPMC13436353
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390